TLR9 — Drug Target

All drugs that target TLR9 — marketed and clinical-stage. Includes 3 drug classes acting on this target.

Drug classes

Immunomodulatory Agent · TLR9 agonist · Immunostimulant

Marketed (1)

• CMP 001 · Pfizer Inc. · Immunomodulatory Agent · Oncology

Phase 3 pipeline (2)

• SCH 697243 · ALK-Abelló A/S · TLR9 agonist · Oncology
  SCH 697243 is a toll-like receptor 9 (TLR9) agonist that activates innate immune responses to enhance anti-tumor immunity.
• MGN1703 treatment · Mologen AG · TLR9 agonist · Oncology
  MGN1703 is a toll-like receptor 9 (TLR9) agonist that activates innate immune responses to enhance anti-tumor immunity.

Phase 2 pipeline (2)

• CpG-ODN · Assistance Publique - Hôpitaux de Paris · Immunostimulant · Immunology
  CpG-ODN is a synthetic DNA molecule that acts as an immunostimulant by activating the immune system through Toll-like receptor 9 (TLR9).
• IMO-2125 · Idera Pharmaceuticals, Inc. · TLR9 agonist · Oncology
  IMO-2125 is a synthetic oligonucleotide that acts as a TLR9 agonist, stimulating the innate immune system.